Imperial College London
Portrait Picture

ProfessorNagyHabib

Faculty of Medicine, Department of Surgery & Cancer

Professor of Hepatobiliary Surgery
 
 
 
//

Contact

 

+44 (0)20 3313 8574nagy.habib

 
 
//

Assistant

 

Mrs Benita White +44 (0)7960 986 387

 
//

Location

 

BN1/18 B BlockHammersmith HospitalHammersmith Campus

//

Summary

 

Publications

Citation

BibTex format

@article{Clift:2023:10.3390/cancers15184438,
author = {Clift, AK and Drymousis, P and von, Roon A and Humphries, A and Goldin, R and Bomanji, J and Leaman, S and Wasan, H and Habib, N and Frilling, A},
doi = {10.3390/cancers15184438},
journal = {Cancers},
title = {Management of small bowel neuroendocrine tumours: 10 years' experience at a tertiary referral centre},
url = {http://dx.doi.org/10.3390/cancers15184438},
volume = {15},
year = {2023}
}
Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - Background: Neuroendocrine tumours (NET) arising from the small bowel are clinically challenging and are often diagnosed at advanced stages. Disease control with surgery alone can be demanding. Multimodal treatment concepts integrating surgery and non-surgical modalities could be of benefit. Method: Retrospective review of consecutive adult patients with SB NET treated at Imperial College Healthcare NHS Trust between 1 January 2010 and 31 December 2019. Data regarding clinicopathological characteristics, treatments, and disease trajectory were extracted and summarised. Overall and progression/recurrence-free survival were estimated at 5 and 10 years. Results: 154 patients were identified, with a median age of 64 years (range 33–87); 135/154 (87.7%) had stage III/IV disease at diagnosis. Surgery was used in 125 individuals (81.2%), typically with either segmental small bowel resection (60.8%) or right hemicolectomy (33.6%) and mesenteric lymphadenectomy for the primary tumour. Systemic and/or liver-directed therapies were used in 126 (81.8%); 60 (47.6%) had more than one line of non-surgical treatment. Median follow-up was 67.2 months (range 3.1–310.4); overall survival at 5 and 10 years was 91.0% (95% CI: 84.9–94.7%) and 82.5% (95% CI: 72.9–88.9%), respectively. Imaging-based median progression-free survival was 42.7 months (95% CI: 24.7 to 72.4); 5-year progression-free survival was 63.4% (95% CI: 55.0–70.6%); 10-year progression-free survival was 18.7% (95% CI: 12.4–26.1). Nineteen patients (12.3%) reached 10 years follow-up without disease recurrence and therefore were considered cured. Conclusions: Most patients with SB NET present in a metastasised stage. Multimodal treatment concepts may be associated with excellent clinical outcomes. Future work should explore optimal approaches to treatment sequencing and patient selection.
AU  - Clift,AK
AU  - Drymousis,P
AU  - von,Roon A
AU  - Humphries,A
AU  - Goldin,R
AU  - Bomanji,J
AU  - Leaman,S
AU  - Wasan,H
AU  - Habib,N
AU  - Frilling,A
DO  - 10.3390/cancers15184438
PY  - 2023///
SN  - 2072-6694
TI  - Management of small bowel neuroendocrine tumours: 10 years' experience at a tertiary referral centre
T2  - Cancers
UR  - http://dx.doi.org/10.3390/cancers15184438
UR  - https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:001071327300001&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=a2bf6146997ec60c407a63945d4e92bb
UR  - https://www.mdpi.com/2072-6694/15/18/4438
UR  - http://hdl.handle.net/10044/1/108728
VL  - 15
ER  -
Download